The odds of receiving a kidney decreased with increasing body mass index.
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.
Patients in the second lowest quintile of testosterone level had a 53% increased death risk compared with those in the highest quintile.
In a small study, the treatment was associated with a 4-fold increase in average ejaculation time.